KETOCONAZOLE 1% SHAMPOO Rx-TO-OTC SWITCH APPLICATION TO BE REVIEWED

Executive Summary

KETOCONAZOLE 1% SHAMPOO Rx-TO-OTC SWITCH APPLICATION TO BE REVIEWED at a Feb. 16 joint meeting of FDA's Nonprescription Drugs Advisory Committee and Dermatologic Drugs Advisory Committee, according to a notice in the Jan. 27 Federal Register. Johnson & Johnson Consumer Products' Rx-to-OTC switch NDA (20-310) covers the use of the ketoconazole 1% formulation for the treatment of dandruff. The Feb. 16 advisory committee meeting will begin at 1 p.m. in Conference Rooms G through J at FDA's Parklawn Building, 5600 Fishers Lane, Rockville, Md.